PhaseBio Pharmaceuticals, Inc.
PHAS · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $2 | $1 |
| % Growth | -96.6% | -86.4% | 253.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $2 | $1 |
| % Margin | 100% | 0.1% | 100% | 100% |
| R&D Expenses | $0 | $72 | $31 | $15 |
| G&A Expenses | $0 | $13 | $11 | $5 |
| SG&A Expenses | $0 | $13 | $11 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $85 | $42 | $20 |
| Operating Income | -$0 | -$85 | -$40 | -$20 |
| % Margin | -1,204.1% | -26,517.5% | -1,683% | -2,940.7% |
| Other Income/Exp. Net | $0 | -$14 | $0 | -$4 |
| Pre-Tax Income | -$0 | -$99 | -$39 | -$24 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$99 | -$39 | -$24 |
| % Margin | -1,210.1% | -30,801.6% | -1,662.3% | -3,569.8% |
| EPS | -0.005 | -3.39 | -1.43 | -4.49 |
| % Growth | 99.9% | -137.1% | 68.2% | – |
| EPS Diluted | -0.005 | -3.39 | -1.43 | -4.49 |
| Weighted Avg Shares Out | 29 | 29 | 27 | 5 |
| Weighted Avg Shares Out Dil | 29 | 29 | 27 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $2 | $0 |
| Interest Expense | -$0 | $1 | $1 | $4 |
| Depreciation & Amortization | $2 | $1 | $0 | $0 |
| EBITDA | $2 | -$97 | -$38 | -$20 |
| % Margin | 15,350.2% | -30,191.3% | -1,609.4% | -2,966.6% |